 Method Retrospective case series of patients with nAMD that were treated with intravitreal injection of anti-VEGF and had a minimum follow up of 48 months. Every patient was initially treated with 3 loading doses of either bevacizumab or ranibizumab, followed by a loose treat and extend regimen. Eyes were divided into 2 groups according to whether aflibercept was later used as a rescue therapy group 2 or not group 1. Patients underwent best-corrected visual acuity BCVA testing, optical coherence tomography, and ophthalmic examination at baseline and all the scheduled follow-up visits. 